Velzatinib granted Orphan Drug Designation (ODD) in Japan in GIST

On November 19, 2026 GSK plc (LSE/NYSE: GSK) reported that velzatinib, a novel, highly selective KIT inhibitor, has received Orphan Drug Designation (ODD) from Japan’s Ministry of Health Labour and Welfare for the treatment of gastrointestinal stromal tumour (GIST). The ODD was supported by data from the ongoing phase I/Ib StrateGIST 1 trial in advanced GIST, which showed promising anti-tumour activity and a promising tolerability profile.1 In addition to the ODD in Japan, velzatinib has been granted US Food and Drug Administration (FDA) Fast Track designation, and US and European Union (EU) ODD.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

GSK is accelerating the development of velzatinib, with phase III trials under way in first- and second-line advanced / metastatic GIST. 2,3 Enrolment in the second-line clinical trial is tracking ahead of schedule, reflecting strong interest in velzatinib from the GIST community, with data expected in the second half of 2027.

Additional data for velzatinib will be shared at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2026 (18-21 November, Seoul, South Korea). Seven abstracts will be presented, including clinical analyses of velzatinib in first- and second-line GIST by KIT mutation, preclinical research on mutation coverage and work on translational biomarkers. These data will further support velzatinib’s development across different KIT mutations and lines of therapy, where resistance and tolerability remain significant challenges.

About velzatinib
Velzatinib is a novel, highly selective KIT inhibitor specifically designed for gastrointestinal stromal tumour (GIST). This monotherapy targets all clinically relevant primary and key secondary KIT mutations, addressing a major unmet need in GIST treatment where tolerability is challenging and resistance arises from diverse KIT mutations.

About GIST
Gastrointestinal stromal tumour (GIST) is a rare type of cancer most commonly arising in the stomach and small intestine. Globally, approximately 80,000 to 120,000 patients are diagnosed with GIST annually.4 80% of GIST cases are driven by mutations in the KIT gene that lead to the growth, proliferation and survival of tumour cells (primary or activating mutations in exons 9 and 11).5 Additionally, about 90% of patients treated in the 1st-line develop new KIT mutations (secondary or resistance mutations in exons 13 and 17) that typically lead to relapse with limited therapeutic options.6 There are no approved tyrosine kinase inhibitors (TKIs) that inhibit the full spectrum of clinically relevant primary and secondary mutations in KIT.

In Japan, the age-adjusted annual incidence of GIST is one of the highest in the world, at approximately 4 per 100,000 people.7 While outcomes for people with GIST have improved over the past two decades, the five-year survival rate remains significantly lower once the disease has spread.8 An additional phase II trial with velzatinib – StrateGIST J – is underway in Japan, evaluating patients whose disease has progressed, or who are intolerant to available treatment options.

(Press release, GlaxoSmithKline, NOV 19, 2026, View Source [SID1234674993])